Literature DB >> 20014067

Pathogenesis of myeloma bone disease.

G David Roodman1.   

Abstract

Multiple myeloma (MM) is the most common cancer to involve bone with up to 90% of patients developing bone lesions. The bone lesions are purely osteolytic in nature and do not heal in the vast majority of patients. Up to 60% of patients develop pathologic fractures over the course of their disease. Bone disease is a hallmark of MM, and myeloma bone disease differs from bone metastasis caused by other tumors. Although myeloma and other osteolytic metastases induce increased osteoclastic bone destruction, in contrast to other tumors, once myeloma tumor burden exceeds 50% in a local area, osteoblast activity is either severely depressed or absent. The basis for this severe imbalance between increased osteoclastic bone resorption and decreased bone formation has been the topic of intensive investigation over the last several years. These studies have helped to identify novel targets for treating myeloma bone disease and will be discussed in this chapter. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20014067     DOI: 10.1002/jcb.22403

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  49 in total

1.  Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myeloma.

Authors:  Joseph K Agyin; Bindu Santhamma; Sudipa S Roy
Journal:  Bioorg Med Chem Lett       Date:  2013-09-21       Impact factor: 2.823

2.  Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss.

Authors:  Muhammad Zahoor; Marita Westhrin; Kristin Roseth Aass; Siv Helen Moen; Kristine Misund; Katarzyna Maria Psonka-Antonczyk; Mariaserena Giliberto; Glenn Buene; Anders Sundan; Anders Waage; Anne-Marit Sponaas; Therese Standal
Journal:  Blood Adv       Date:  2017-12-13

Review 3.  Bone disease from monoclonal gammopathy of undetermined significance to multiple myeloma: pathogenesis, interventions, and future opportunities.

Authors:  Alex R Minter; Haley Simpson; Brendan M Weiss; Ola Landgren
Journal:  Semin Hematol       Date:  2011-01       Impact factor: 3.851

Review 4.  Sclerostin expression and functions beyond the osteocyte.

Authors:  Megan M Weivoda; Stephanie J Youssef; Merry Jo Oursler
Journal:  Bone       Date:  2016-11-23       Impact factor: 4.398

Review 5.  Multiple Myeloma and Bone: The Fatal Interaction.

Authors:  Silvia Marino; G David Roodman
Journal:  Cold Spring Harb Perspect Med       Date:  2018-08-01       Impact factor: 6.915

6.  Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma.

Authors:  Meera Mohan; Rohan S Samant; Donghoon Yoon; Amy F Buros; Antonio Branca; Corey O Montgomery; Richard Nicholas; Larry J Suva; Roy Morello; Sharmilan Thanendrarajan; Carolina Schinke; Shmuel Yaccoby; Frits van Rhee; Faith E Davies; Gareth J Morgan; Maurizio Zangari
Journal:  J Bone Miner Res       Date:  2017-03-27       Impact factor: 6.741

7.  Mechanisms of multiple myeloma bone disease.

Authors:  Deborah L Galson; Rebecca Silbermann; G David Roodman
Journal:  Bonekey Rep       Date:  2012-08-01

8.  Intravascular B-cell lymphoma with hypercalcemia as the initial presentation.

Authors:  Yoshiaki Chinen; Mitsushige Nakao; Mio Sugitani-Yamamoto; Miki Kiyota; Shigeo Horiike; Junya Kuroda; Masafumi Taniwaki
Journal:  Int J Hematol       Date:  2011-11-03       Impact factor: 2.490

9.  Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.

Authors:  Michelle M McDonald; Michaela R Reagan; Scott E Youlten; Sindhu T Mohanty; Anja Seckinger; Rachael L Terry; Jessica A Pettitt; Marija K Simic; Tegan L Cheng; Alyson Morse; Lawrence M T Le; David Abi-Hanna; Ina Kramer; Carolyne Falank; Heather Fairfield; Irene M Ghobrial; Paul A Baldock; David G Little; Michaela Kneissel; Karin Vanderkerken; J H Duncan Bassett; Graham R Williams; Babatunde O Oyajobi; Dirk Hose; Tri G Phan; Peter I Croucher
Journal:  Blood       Date:  2017-05-17       Impact factor: 22.113

10.  In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma.

Authors:  Samantha Pozzi; Mariateresa Fulciniti; Hua Yan; Sonia Vallet; Homare Eda; Kishan Patel; Loredana Santo; Diana Cirstea; Teru Hideshima; Linda Schirtzinge; Stuart Kuhstoss; Kenneth C Anderson; Nikhil Munshi; David Scadden; Henry M Kronenberg; Noopur Raje
Journal:  Bone       Date:  2013-01-17       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.